Last $25.78 USD
Change Today +0.20 / 0.78%
Volume 89.6K
SGNT On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 4:00 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

1901 North Roselle Road

Suite 700

Schaumburg, IL 60195

United States

Phone: 847-908-1600

Fax: 847-908-1601

Sagent Pharmaceuticals, Inc. operates as a specialty pharmaceutical company. The company focuses on developing, manufacturing, sourcing, and marketing injectable pharmaceutical products in the United States of America. Products As of December 31, 2013, the company’s product portfolio has grown to a total of 53 products which can be classified into the following 3 product categories: anti-infective, oncology and critical care. The company’s anti-infective products assist in the treatment of various infections and related symptoms, its oncology products are used in the treatment of cancer and cancer-related medical problems, and its critical care products are used in various critical care applications and include anesthetics, cardiac medications, steroidal products and sedatives. Anti-Infective Products Cefepime: Cefepime is a fourth-generation cephalosporin, an antibiotic used to treat various infections, including infections of the urinary tract, skin and skin structure, as well as moderate to severe pneumonia, complicated intra-abdominal infections, and as empiric therapy for febrile neutropenic patients. Cefepime is the generic equivalent of Elan Corporation, plc’s MAXIPIME. Levofloxacin: Levofloxacin is a fluoroquinolone antibacterial indicated in adults 18 years of age or older with infections caused by designated, susceptible bacteria, including: nosocomial and community acquired pneumonia, sinusitis, chronic bronchitis, skin and skin structure infections, prostatitis, urinary tract infection and pyelonephritis. Levofloxacin is the generic equivalent of Johnson & Johnson’s Levaquin. Oncology Products Docetaxel: Docetaxel is an antineoplastic agent used on its own to treat advanced or metastatic breast cancer after chemotherapy failure, or in connection with other agents in the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, advanced squamous cell carcinoma of the head and neck cancer. Docetaxel is the generic equivalent of Sanofi-Aventis’ Taxotere. The company launched Docetaxel in 2013. Leucovorin Calcium: Leucovorin Calcium is a folic acid derivative used to prevent harmful effects of methotrexate when methotrexate is used to treat certain types of cancer. Leucovorin Calcium is also used to treat people who have accidentally received an overdose of methotrexate or similar medications. Zoledronic Acid: Zoledronic Acid is a bisphosphonate given intravenously to prevent skeletal fractures in patients with cancers, such as multiple myeloma and prostate cancer, as well as for treating osteoporosis. Zoledronic Acid 4mg is the generic equivalent of Novartis’ Zometa, and Zoledronic Acid 5mg is the generic equivalent of Novartis’ Reclast. The company launched zoledronic acid at market formation in a 4mg vial presentation in 2013, a 4mg per 100mL premix bag presentation in 2013, and a 5mg per 100mL premix bag presentation in 2013. Critical Care Products Heparin: Heparin is an anticoagulant used to prevent and treat blood clotting, especially during and after surgery and dialysis. In 2010, the company launched nine different presentations of heparin sodium injection in latex-free vials, including 1,000 USP units per mL, 10,000 USP units per 10 mL, 30,000 USP units per 30 mL, 10,000 USP units per mL, 40,000 USP units per 4 mL, 5,000 USP units per mL, 50,000 USP units per 10 mL, 2,000 USP units per 2 mL and 20,000 USP units per mL. Sales and Marketing The company markets its products to group purchasing organizations (GPOs), specialty distributors and a diverse group of end-user customers. The company’s major U.S. GPOs include AmeriNet, Inc.; HealthTrust Purchasing Group; MedAssets Inc.; Novation, LLC; and Premier, Inc. Customers As is typical in the pharmaceutical industry, the company distributes its products primarily through pharmaceutical wholesalers and, to a lesser extent, specialty distributors that focus on particular therapeutic product categories, for use by various end-users, including U.S. hospitals, integrated delivery networks and alternative site facilities. For the year ended December 31, 2013, the products the company sold through its three major wholesalers, AmerisourceBergen Corp. (Amerisource), Cardinal Health Inc. (Cardinal Health) and McKesson Corp. (McKesson). Intellectual Property The company’s trademarks include Sagent Pharmaceuticals, Sagent, Injectables Excellence, Discover Injectables Excellence and PreventIV Measures. Joint Venture In 2007, the company and Strides Arcolab International Limited, a company based in the United Kingdom and a wholly-owned subsidiary of Strides Arcolab Limited (Strides), entered into a joint venture agreement pursuant to which the parties formed Sagent Agila LLC (Sagent Agila). In 2013, Mylan Inc. acquired Agila Specialties Private Limited (Agila), the manufacturer of products for Sagent Agila, and Strides Inc., the company’s joint venture partner, from Strides. Key Suppliers and Marketing Partners Two of the company’s business partners, A.C.S. Dobfar S.p.a. (Dobfar) and Gland Pharma Limited (Gland), provided the company with products. The company also has agreement with Actavis LLC. Competition The company’s principal competitors include Fresenius Kabi (Fresenius), a division of Fresenius SE, Hospira, Inc. (Hospira), Pfizer Inc. (Pfizer), Sandoz International GmbH (Sandoz), a division of Novartis AG, Teva Pharmaceutical Industries Ltd. (Teva) and West-Ward Pharmaceutical Corp (West-Ward), a subsidiary of Hikma PLC. History The company was founded in 2006 as Sagent Holding Co., a Cayman Islands company. It was reincorporated as Sagent Pharmaceuticals, Inc., a Delaware corporation. The company was incorporated in 2006.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGNT:US $25.78 USD +0.20

SGNT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Lannett Co Inc $42.13 USD -0.16
OraSure Technologies Inc $10.28 USD +0.02
Pfizer Ltd/India 2,038 INR +22.40
SciClone Pharmaceuticals Inc $8.76 USD +0.12
Sucampo Pharmaceuticals Inc $13.61 USD -0.14
View Industry Companies
 

Industry Analysis

SGNT

Industry Average

Valuation SGNT Industry Range
Price/Earnings 61.2x
Price/Sales 3.0x
Price/Book 3.3x
Price/Cash Flow 59.7x
TEV/Sales 2.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAGENT PHARMACEUTICALS INC, please visit www.sagentpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.